Wellington Management Group LLP Sells 257,244 Shares of Becton, Dickinson and Company $BDX

Wellington Management Group LLP trimmed its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 3.9% during the second quarter, Holdings Channel.com reports. The firm owned 6,357,986 shares of the medical instruments supplier’s stock after selling 257,244 shares during the period. Wellington Management Group LLP’s holdings in Becton, Dickinson and Company were worth $962,154,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of BDX. Auto Owners Insurance Co raised its position in shares of Becton, Dickinson and Company by 22,225.2% during the fourth quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier’s stock worth $790,079,000 after acquiring an additional 40,528,680 shares during the last quarter. BlackRock Inc. acquired a new position in shares of Becton, Dickinson and Company during the second quarter valued at $3,721,533,000. State Street Corp boosted its holdings in Becton, Dickinson and Company by 0.8% in the fourth quarter. State Street Corp now owns 13,989,132 shares of the medical instruments supplier’s stock valued at $2,714,871,000 after acquiring an additional 116,737 shares during the last quarter. First Eagle Investment Management LLC boosted its holdings in Becton, Dickinson and Company by 16.5% in the fourth quarter. First Eagle Investment Management LLC now owns 11,646,000 shares of the medical instruments supplier’s stock valued at $2,260,139,000 after acquiring an additional 1,651,592 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in Becton, Dickinson and Company by 0.8% in the fourth quarter. Geode Capital Management LLC now owns 6,885,361 shares of the medical instruments supplier’s stock worth $1,331,165,000 after purchasing an additional 53,884 shares during the period. 86.97% of the stock is owned by institutional investors.

Insider Activity

In other news, EVP Roland Goette sold 2,438 shares of Becton, Dickinson and Company stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the transaction, the executive vice president directly owned 14,856 shares of the company’s stock, valued at $2,686,559.04. This trade represents a 14.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Michael David Garrison sold 1,100 shares of the business’s stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the completion of the transaction, the executive vice president directly owned 13,172 shares of the company’s stock, valued at $1,918,633.52. This trade represents a 7.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 11,869 shares of company stock worth $1,994,719 in the last ninety days. Company insiders own 0.40% of the company’s stock.

Wall Street Analyst Weigh In

BDX has been the subject of several recent research reports. UBS Group started coverage on Becton, Dickinson and Company in a report on Tuesday, July 28th. They set a “buy” rating and a $190.00 price objective for the company. Citigroup reaffirmed a “buy” rating on shares of Becton, Dickinson and Company in a research note on Thursday, August 13th. TD Cowen boosted their price target on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a research note on Wednesday, August 5th. Stifel Nicolaus set a $195.00 price objective on shares of Becton, Dickinson and Company in a report on Friday, August 7th. Finally, Royal Bank Of Canada raised their price objective on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a research note on Thursday, August 13th. Eight equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $185.67.

Becton, Dickinson and Company Trading Up 0.8%

NYSE:BDX opened at $189.71 on Friday. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $193.07. The business’s 50-day moving average price is $166.14 and its two-hundred day moving average price is $160.53. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. The firm has a market capitalization of $52.27 billion, a price-to-earnings ratio of 57.14, a PEG ratio of 13.26 and a beta of 0.19.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. The firm had revenue of $4.98 billion for the quarter, compared to analysts’ expectations of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The company’s revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the business earned $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, equities analysts expect that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be issued a dividend of $1.05 per share. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.2%. Becton, Dickinson and Company’s payout ratio is currently 126.51%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.